Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Public ClinicalTrials.gov record NCT03833154. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.
Study identification
- NCT ID
- NCT03833154
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 724 participants
Conditions and interventions
Conditions
Interventions
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2019 (Actual)
- Primary completion
- Oct 31, 2028 (Estimated)
- Completion
- Oct 31, 2028 (Estimated)
- Last update posted
- Jul 20, 2026
2019 – 2028
United States locations
- U.S. sites
- 80
- U.S. states
- 35
- U.S. cities
- 75
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tuscaloosa | Alabama | 35401 | — |
| Research Site | Chandler | Arizona | 85224 | — |
| Research Site | Phoenix | Arizona | 85004 | — |
| Research Site | Tucson | Arizona | 85719 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Long Beach | California | 90806 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | San Diego | California | 92123 | — |
| Research Site | Newark | Delaware | 10709 | — |
| Research Site | Washington D.C. | District of Columbia | 20010 | — |
| Research Site | Bay Pines | Florida | 33744 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Decatur | Illinois | 62526 | — |
| Research Site | Elmhurst | Illinois | 60126 | — |
| Research Site | Naperville | Illinois | 60540 | — |
| Research Site | Fort Wayne | Indiana | 46845 | — |
| Research Site | Cedar Rapids | Iowa | 52403 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Elizabethtown | Kentucky | 42701 | — |
| Research Site | Lexington | Kentucky | 40503 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Metairie | Louisiana | 70006 | — |
| Research Site | New Orleans | Louisiana | 70121 | — |
| Research Site | South Portland | Maine | 04106 | — |
| Research Site | Annapolis | Maryland | 21401 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Rosedale | Maryland | 21237 | — |
| Research Site | Silver Spring | Maryland | 20910 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Ann Arbor | Michigan | 48197 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Royal Oak | Michigan | 48073 | — |
| Research Site | Duluth | Minnesota | 55805 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Omaha | Nebraska | 68105 | — |
| Research Site | Las Vegas | Nevada | 89169 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | Camden | New Jersey | 08103 | — |
| Research Site | Paramus | New Jersey | 07652 | — |
| Research Site | Albany | New York | 12206 | — |
| Research Site | East Syracuse | New York | 13057 | — |
| Research Site | New Hyde Park | New York | 11042 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Stony Brook | New York | 11794 | — |
| Research Site | Syracuse | New York | 13210 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | The Bronx | New York | 10467 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Grand Forks | North Dakota | 58201 | — |
| Research Site | Akron | Ohio | 44304 | — |
| Research Site | Blue Ash | Ohio | 45242 | — |
| Research Site | Cincinnati | Ohio | 45219 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Portland | Oregon | 97210 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Sioux Falls | South Dakota | 57105 | — |
| Research Site | Watertown | South Dakota | 57201 | — |
| Research Site | Austin | Texas | 78745 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Sherman | Texas | 75090 | — |
| Research Site | Burlington | Vermont | 05401 | — |
| Research Site | Richmond | Virginia | 23249 | — |
| Research Site | Bellingham | Washington | 98225 | — |
| Research Site | Seattle | Washington | 98195 | — |
| Research Site | Spokane Valley | Washington | 99216 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 129 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03833154, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03833154 live on ClinicalTrials.gov.